Colm Andrews
Data Scientist
Colm is a data scientist at the Bennett Institute. He has 5 years of experience working with NHS data as a data analyst with the Eye Research Group Oxford and medical statistician with the Cancer Epidemiology Unit in the Nuffield Department of Population Health. He has an MSc in Evidence Based Healthcare from the University of Oxford.
Papers by Colm Andrews
- The impact of COVID-19 on medication reviews in English primary care
- Comparative safety and effectiveness of Pfizer BA.4-5 versus Sanofi during the spring 2023 COVID-19 booster vaccination programme in England
- Changes in opioid prescribing during the COVID-19 pandemic in England
- Measuring BMI in 22 million patients in England
- OpenSAFELY: a platform for analysing electronic health records designed for reproducible research
- Trends in inequalities in avoidable hospitalisations across the COVID-19 pandemic
- Consistency, completeness and external validity of ethnicity recording in NHS primary care records
- Impact of the COVID-19 pandemic on antipsychotic prescribing in individuals with autism, dementia, learning disability, serious mental illness or living in a care home
- Impact of COVID-19 on recorded blood pressure screening and hypertension management in England
- A National Audit of Pancreatic Enzyme Prescribing in Pancreatic Cancer from 2015 to 2023 in England
- Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022
- Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England
- First dose COVID-19 vaccine coverage amongst adolescents and children in England
- Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings
- Incidence and management of inflammatory arthritis in England before and during the COVID-19 pandemic
- Representativeness of electronic health record platform OpenSAFELY-TPP data compared to the population of England
- Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England
- Effectiveness of BNT162b2 booster doses in England